{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:17:57Z","timestamp":1792703877316,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with diabetes and acute coronary syndrome (ACS) are at high risk for subsequent heart failure. Apabetalone is a selective inhibitor of bromodomain and extra-terminal (BET) proteins, epigenetic regulators of gene expression. Preclinical data suggest that apabetalone exerts favorable effects on pathways related to myocardial structure and function and therefore could impact subsequent heart failure events. The effect of apabetalone on heart failure events after an ACS is not currently known.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The phase 3 BETonMACE trial was a double-blind, randomized comparison of apabetalone versus placebo on the incidence of major adverse cardiovascular events (MACE) in 2425 patients with a recent ACS and diabetes. This prespecified secondary analysis investigated the impact of apabetalone on hospitalization for congestive heart failure, not previously studied.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Patients (age 62\u00a0years, 74.4% males, 90% high-intensity statin use, LDL-C 70.3\u00a0mg\/dL, HDL-C 33.3\u00a0mg\/dL and HbA1c 7.3%) were followed for an average 26\u00a0months. Apabetalone treated patients experienced the nominal finding of a lower rate of first hospitalization for heart failure (2.4% vs. 4.0%, HR 0.59 [95%CI 0.38\u20130.94], P\u2009=\u20090.03), total number of hospitalizations for heart failure (35 vs. 70, HR 0.47 [95%CI 0.27\u20130.83], P\u2009=\u20090.01) and the combination of cardiovascular death or hospitalization for heart failure (5.7% vs. 7.8%, HR 0.72 [95%CI 0.53\u20130.98], P\u2009=\u20090.04).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Apabetalone treatment was associated with fewer hospitalizations for heart failure in patients with type 2 diabetes and recent ACS. Future studies are warranted to define the potential for BET inhibition with apabetalone to prevent heart failure in patients with diabetes and ACS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-020-01199-x","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T21:05:33Z","timestamp":1610053533000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study"],"prefix":"10.1186","volume":"20","author":[{"name":"the BETonMACE Investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin A.","family":"Buhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry N.","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan O.","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamyar","family":"Kalantar-Zadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Kulikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"key":"1199_CR1","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1161\/CIR.0000000000000691","volume":"140","author":"SM Dunlay","year":"2019","unstructured":"Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS, Deswal A, Dickson VV, Kosiborod MN, Lekavich CL, McCoy RG, Mentz RJ, Pina IL, American Heart Association Heart F, Transplantation Committee of the Council on Clinical C, Council on C, Stroke N and the Heart Failure Society of A. Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update. Circulation. 2019;140:e294\u2013324.","journal-title":"Circulation"},{"key":"1199_CR2","doi-asserted-by":"publisher","first-page":"407","DOI":"10.4330\/wjc.v9.i5.407","volume":"9","author":"TJ Cahill","year":"2017","unstructured":"Cahill TJ, Kharbanda RK. Heart failure after myocardial infarction in the era of primary percutaneous coronary intervention: Mechanisms, incidence and identification of patients at risk. World J Cardiol. 2017;9:407\u201315.","journal-title":"World J Cardiol"},{"key":"1199_CR3","first-page":"1","volume":"11","author":"A Torabi","year":"2014","unstructured":"Torabi A, Cleland JG, Rigby AS, Sherwi N. Development and course of heart failure after a myocardial infarction in younger and older people. J Geriatr Cardiol. 2014;11:1\u201312.","journal-title":"J Geriatr Cardiol"},{"key":"1199_CR4","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","volume":"70","author":"KS Shah","year":"2017","unstructured":"Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, Devore AD, Yancy CW, Fonarow GC. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70:2476\u201386.","journal-title":"J Am Coll Cardiol"},{"key":"1199_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13584-017-0149-0","volume":"6","author":"LD Bash","year":"2017","unstructured":"Bash LD, Weitzman D, Blaustein RO, Sharon O, Shalev V, Chodick G. Comprehensive healthcare resource use among newly diagnosed congestive heart failure. Isr J Health Policy Res. 2017;6:26.","journal-title":"Isr J Health Policy Res"},{"key":"1199_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ahj.2017.01.003","volume":"186","author":"JB Echouffo-Tcheugui","year":"2017","unstructured":"Echouffo-Tcheugui JB, Bishu KG, Fonarow GC, Egede LE. Trends in health care expenditure among US adults with heart failure: the medical expenditure panel survey 2002\u20132011. Am Heart J. 2017;186:63\u201372.","journal-title":"Am Heart J"},{"key":"1199_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017. Cardiovasc Diabetol. 2018;17:83.","journal-title":"Cardiovasc Diabetol"},{"key":"1199_CR8","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1128\/MCB.01365-08","volume":"29","author":"B Huang","year":"2009","unstructured":"Huang B, Yang XD, Zhou MM, Ozato K, Chen LF. Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol Cell Biol. 2009;29:1375\u201387.","journal-title":"Mol Cell Biol"},{"key":"1199_CR9","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/nature09589","volume":"468","author":"E Nicodeme","year":"2010","unstructured":"Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, Chandwani R, Marazzi I, Wilson P, Coste H, White J, Kirilovsky J, Rice CM, Lora JM, Prinjha RK, Lee K, Tarakhovsky A. Suppression of inflammation by a synthetic histone mimic. Nature. 2010;468:1119\u201323.","journal-title":"Nature"},{"key":"1199_CR10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.molcel.2014.08.024","volume":"56","author":"JD Brown","year":"2014","unstructured":"Brown JD, Lin CY, Duan Q, Griffin G, Federation A, Paranal RM, Bair S, Newton G, Lichtman A, Kung A, Yang T, Wang H, Luscinskas FW, Croce K, Bradner JE, Plutzky J. NF-kappaB directs dynamic super enhancer formation in inflammation and atherogenesis. Mol Cell. 2014;56:219\u201331.","journal-title":"Mol Cell"},{"key":"1199_CR11","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/s41467-017-01629-7","volume":"8","author":"S Das","year":"2017","unstructured":"Das S, Senapati P, Chen Z, Reddy MA, Ganguly R, Lanting L, Mandi V, Bansal A, Leung A, Zhang S, Jia Y, Wu X, Schones DE, Natarajan R. Regulation of angiotensin II actions by enhancers and super-enhancers in vascular smooth muscle cells. Nat Commun. 2017;8:1467.","journal-title":"Nat Commun"},{"key":"1199_CR12","doi-asserted-by":"publisher","first-page":"e100293","DOI":"10.15252\/embj.2018100293","volume":"38","author":"A Dey","year":"2019","unstructured":"Dey A, Yang W, Gegonne A, Nishiyama A, Pan R, Yagi R, Grinberg A, Finkelman FD, Pfeifer K, Zhu J, Singer D, Zhu J, Ozato K. BRD4 directs hematopoietic stem cell development and modulates macrophage inflammatory responses. EMBO J. 2019;38:e100293.","journal-title":"EMBO J"},{"key":"1199_CR13","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1016\/j.jacc.2010.02.035","volume":"55","author":"D Bailey","year":"2010","unstructured":"Bailey D, Jahagirdar R, Gordon A, Hafiane A, Campbell S, Chatur S, Wagner GS, Hansen HC, Chiacchia FS, Johansson J, Krimbou L, Wong NC, Genest J. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol. 2010;55:2580\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"1199_CR14","doi-asserted-by":"publisher","first-page":"e83190","DOI":"10.1371\/journal.pone.0083190","volume":"8","author":"KG McLure","year":"2013","unstructured":"McLure KG, Gesner EM, Tsujikawa L, Kharenko OA, Attwell S, Campeau E, Wasiak S, Stein A, White A, Fontano E, Suto RK, Wong NC, Wagner GS, Hansen HC, Young PR. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. PLoS ONE. 2013;8:e83190.","journal-title":"PLoS ONE"},{"key":"1199_CR15","doi-asserted-by":"publisher","first-page":"19754","DOI":"10.1073\/pnas.1310658110","volume":"110","author":"S Picaud","year":"2013","unstructured":"Picaud S, Wells C, Felletar I, Brotherton D, Martin S, Savitsky P, Diez-Dacal B, Philpott M, Bountra C, Lingard H, Fedorov O, Muller S, Brennan PE, Knapp S, Filippakopoulos P. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc Natl Acad Sci USA. 2013;110:19754\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1199_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.atherosclerosis.2014.06.008","volume":"236","author":"R Jahagirdar","year":"2014","unstructured":"Jahagirdar R, Zhang H, Azhar S, Tobin J, Attwell S, Yu R, Wu J, McLure KG, Hansen HC, Wagner GS, Young PR, Srivastava RA, Wong NC, Johansson J. A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice. Atherosclerosis. 2014;236:91\u2013100.","journal-title":"Atherosclerosis"},{"key":"1199_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.atherosclerosis.2016.01.036","volume":"247","author":"D Gilham","year":"2016","unstructured":"Gilham D, Wasiak S, Tsujikawa LM, Halliday C, Norek K, Patel RG, Kulikowski E, Johansson J, Sweeney M, Wong NC, Gordon A, McLure K, Young P. RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I\/HDL and represses pathways that contribute to cardiovascular disease. Atherosclerosis. 2016;247:48\u201357.","journal-title":"Atherosclerosis"},{"key":"1199_CR18","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.dib.2016.07.047","volume":"8","author":"S Wasiak","year":"2016","unstructured":"Wasiak S, Gilham D, Tsujikawa LM, Halliday C, Norek K, Patel RG, McLure KG, Young PR, Gordon A, Kulikowski E, Johansson J, Sweeney M, Wong NC. Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes. Data Brief. 2016;8:1280\u20138.","journal-title":"Data Brief"},{"key":"1199_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s12265-017-9755-z","volume":"10","author":"S Wasiak","year":"2017","unstructured":"Wasiak S, Gilham D, Tsujikawa LM, Halliday C, Calosing C, Jahagirdar R, Johansson J, Sweeney M, Wong NC, Kulikowski E. Downregulation of the complement cascade in vitro, in mice and in patients with cardiovascular disease by the BET protein inhibitor apabetalone (RVX-208). J Cardiovasc Transl Res. 2017;10:337\u201347.","journal-title":"J Cardiovasc Transl Res"},{"key":"1199_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.atherosclerosis.2018.11.002","volume":"280","author":"D Gilham","year":"2019","unstructured":"Gilham D, Tsujikawa LM, Sarsons CD, Halliday C, Wasiak S, Stotz SC, Jahagirdar R, Sweeney M, Johansson JO, Wong NCW, Kalantar-Zadeh K, Kulikowski E. Apabetalone downregulates factors and pathways associated with vascular calcification. Atherosclerosis. 2019;280:75\u201384.","journal-title":"Atherosclerosis"},{"key":"1199_CR21","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13148-019-0696-z","volume":"11","author":"LM Tsujikawa","year":"2019","unstructured":"Tsujikawa LM, Fu L, Das S, Halliday C, Rakai BD, Stotz SC, Sarsons CD, Gilham D, Daze E, Wasiak S, Studer D, Rinker KD, Sweeney M, Johansson JO, Wong NCW, Kulikowski E. Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism. Clin Epigenet. 2019;11:102.","journal-title":"Clin Epigenet"},{"key":"1199_CR22","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.cell.2013.07.013","volume":"154","author":"P Anand","year":"2013","unstructured":"Anand P, Brown JD, Lin CY, Qi J, Zhang R, Artero PC, Alaiti MA, Bullard J, Alazem K, Margulies KB, Cappola TP, Lemieux M, Plutzky J, Bradner JE, Haldar SM. BET bromodomains mediate transcriptional pause release in heart failure. Cell. 2013;154:569\u201382.","journal-title":"Cell"},{"key":"1199_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.yjmcc.2018.12.002","volume":"127","author":"S Song","year":"2019","unstructured":"Song S, Liu L, Yu Y, Zhang R, Li Y, Cao W, Xiao Y, Fang G, Li Z, Wang X, Wang Q, Zhao X, Chen L, Wang Y, Wang Q. Inhibition of BRD4 attenuates transverse aortic constriction- and TGF-beta-induced endothelial-mesenchymal transition and cardiac fibrosis. J Mol Cell Cardiol. 2019;127:83\u201396.","journal-title":"J Mol Cell Cardiol"},{"key":"1199_CR24","doi-asserted-by":"publisher","first-page":"e965","DOI":"10.1161\/CIRCULATIONAHA.119.042642","volume":"140","author":"KK Ray","year":"2019","unstructured":"Ray KK, Nicholls SJ, Ginsberg HN, Johansson JO, Kalantar-Zadeh K, Kulikowski E, Toth PP, Wong N, Sweeney M, Schwartz GG. Effect of BET protein inhibition with apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes\u2014results of the BETonMACE trial. Circulation. 2019;140:e965\u20131011.","journal-title":"Circulation"},{"key":"1199_CR25","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1001\/jama.2020.3308","volume":"323","author":"KK Ray","year":"2020","unstructured":"Ray KK, Nicholls SJ, Buhr KA, Ginsberg HN, Johansson JO, Kalantar-Zadeh K, Kulikowski E, Toth PP, Wong N, Sweeney M, Schwartz GG, Investigators BE and Committees. Effect of apabetalone added to standard therapy on major adverse cardiovascular events in patients with recent acute coronary syndrome and type 2 diabetes: a randomized clinical trial. JAMA. 2020;323:1565\u201373.","journal-title":"JAMA"},{"key":"1199_CR26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ahj.2019.08.001","volume":"217","author":"KK Ray","year":"2019","unstructured":"Ray KK, Nicholls SJ, Ginsberg HD, Johansson JO, Kalantar-Zadeh K, Kulikowski E, Toth PP, Wong N, Cummings JL, Sweeney M, Schwartz GG. Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. Am Heart J. 2019;217:72\u201383.","journal-title":"Am Heart J"},{"key":"1199_CR27","first-page":"CD012721","volume":"6","author":"N Martin","year":"2018","unstructured":"Martin N, Manoharan K, Thomas J, Davies C, Lumbers RT. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database Syst Rev. 2018;6:CD012721.","journal-title":"Cochrane Database Syst Rev"},{"key":"1199_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-019-09900-3","author":"J-L Feng","year":"2019","unstructured":"Feng J-L, Qin X. Association between evidence-based medication at discharge and outcomes in patients with heart failure: a systematic review and meta-analysis. Heart Failure Rev. 2019. https:\/\/doi.org\/10.1007\/s10741-019-09900-3.","journal-title":"Heart Failure Rev"},{"key":"1199_CR29","doi-asserted-by":"publisher","first-page":"eaah5084","DOI":"10.1126\/scitranslmed.aah5084","volume":"9","author":"Q Duan","year":"2017","unstructured":"Duan Q, McMahon S, Anand P, Shah H, Thomas S, Salunga HT, Huang Y, Zhang R, Sahadevan A, Lemieux ME, Brown JD, Srivastava D, Bradner JE, McKinsey TA, Haldar SM. BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure. Sci Transl Med. 2017;9:eaah5084.","journal-title":"Sci Transl Med"},{"key":"1199_CR30","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.celrep.2016.06.074","volume":"16","author":"MS Stratton","year":"2016","unstructured":"Stratton MS, Lin CY, Anand P, Tatman PD, Ferguson BS, Wickers ST, Ambardekar AV, Sucharov CC, Bradner JE, Haldar SM, McKinsey TA. Signal-dependent recruitment of BRD4 to cardiomyocyte super-enhancers is suppressed by a MicroRNA. Cell Rep. 2016;16:1366\u201378.","journal-title":"Cell Rep"},{"key":"1199_CR31","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1161\/CIRCRESAHA.119.315125","volume":"125","author":"MS Stratton","year":"2019","unstructured":"Stratton MS, Bagchi RA, Felisbino MB, Hirsch RA, Smith HE, Riching AS, Enyart BY, Koch KA, Cavasin MA, Alexanian M, Song K, Qi J, Lemieux ME, Srivastava D, Lam MPY, Haldar SM, Lin CY, McKinsey TA. Dynamic chromatin targeting of BRD4 stimulates cardiac fibroblast activation. Circ Res. 2019;125:662\u201377.","journal-title":"Circ Res"},{"key":"1199_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.yjmcc.2013.07.017","volume":"63","author":"JI Spiltoir","year":"2013","unstructured":"Spiltoir JI, Stratton MS, Cavasin MA, Demos-Davies K, Reid BG, Qi J, Bradner JE, McKinsey TA. BET acetyl-lysine binding proteins control pathological cardiac hypertrophy. J Mol Cell Cardiol. 2013;63:175\u20139.","journal-title":"J Mol Cell Cardiol"},{"key":"1199_CR33","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","volume":"136","author":"Y Lytvyn","year":"2017","unstructured":"Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation. 2017;136:1643\u201358.","journal-title":"Circulation"},{"key":"1199_CR34","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, Bohm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukat A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O\u2019Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjostrand M, Langkilde AM, Committees D-HT and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008.","journal-title":"N Engl J Med."}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01199-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-020-01199-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01199-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T21:14:42Z","timestamp":1610054082000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-020-01199-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1199"],"URL":"https:\/\/doi.org\/10.1186\/s12933-020-01199-x","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"15 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This is a subsequent analysis of a multicenter clinical trial. All sites required local ethics committee approval prior to study initiation and all participating patients provided informed, written consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SJN reports research grants from AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience and honoraria from AstraZeneca, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim. GGS reports grants to his institution from Resverlogix, Roche, Sanofi and The Medicines Company. GGS also has a pending patent US 62\/806,313 \"Methods for Reducing Cardiovascular Risk\" assigned in full to the University of Colorado. KAB reports research grants from Resverlogix, The Medicines Company, GlaxoSmithKline, Pfizer, BioCardia, Amgen and Cytokinetics. HNG reports honoraria from Resverlogix. JOJ, EK, NW and MS are employees of Resverlogix. KK-Z reports honoraria from Abbott, Abbvie, Alexion, Amgen, AstraZeneca, Aveo, Chugai, DaVita, Fresenius Medical Services, Genentech, Haymarket, Hospira, Kabi, Keryx, Novartis, Pfizer, Relypsa, Resverlogix, Sandoz, Sanofi, Vifor, ZS-Pharma, UpToDate, Baxter, Dr Schaer, Amag Pharma and grants from Shire, PCORI and NIH. PPT reports honoraria from Resverlogix, Amarin, Amgen, Kowa, Merck, Novo-Nordisk, Regeneron, Sanofi, Theravance. KKR reports honoraria from Resverlogix, Aegerion, Amgen, Pfizer, AstraZeneca, Cerenis, Akcea, The Medicines Company, Kowa, Novartis, Cipla, Eli Lilly, Algorithm, Takeda, Boehringer Ingelheim, Abbvie, Silence Therapeutics, Dr Reddys, Bayer, Daiichi Sankyo, Esperion, Zuelling Pharma, Sanofi-Regeneron and Merck and grants from Sanofi-Regeneron and Merck.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}